Davis Polk advised Valeant Pharmaceuticals International, Inc. (“Valeant”) in connection with a refinancing transaction pursuant to which its indirect wholly owned subsidiary, Valeant Pharmaceuticals International (the…
Valeant Pharmaceuticals International, Inc.’s $1.5 Billion Refinancing
